Pharmacokinetic boosting of osimertinib with cobicistat in patients with non-small cell lung cancer: The OSIBOOST trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Pharmacokinetic boosting of osimertinib with cobicistat in patients with non-small cell lung cancer: The OSIBOOST trial

Published:2022-09 Issue: Volume:171 Page:97-102
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

van Veelen Ard,Gulikers Judith,Hendriks Lizza E.L.,Dursun Safiye,Ippel Juanita,Smit Egbert F.,Dingemans Anne-Marie C.,van Geel Robin,Croes Sander

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference28 articles.

1. Overview of current systemic management of EGFR-mutant NSCLC;Hsu;Ann. Oncol.,2018

2. Oncogene-addicted non-small-cell lung cancer: treatment opportunities and future perspectives;Ferrara;Cancers (Basel).,2020

3. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer;Mok;N. Engl. J. Med.,2017

4. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer;Soria;N. Engl. J. Med.,2018

5. Osimertinib in resected EGFR-mutated Non-Small-Cell Lung Cancer;Wu;N. Engl. J. Med.,2020

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systematic Evaluation of Osimertinib Population Pharmacokinetic Models in a Cohort of Dutch Adults with Non-Small Cell Lung Cancer;European Journal of Drug Metabolism and Pharmacokinetics;2024-06-15

2. Atazanavir/Ritonavir Increased Tizoxanide Exposure from Oral Nitazoxanide through Pharmacokinetic Interaction in Healthy Volunteers;Future Pharmacology;2024-02-22

3. Pharmacokinetic boosting of olaparib: A randomised, cross-over study (PROACTIVE-study);European Journal of Cancer;2023-11

4. Atazanavir/ritonavir increased tizoxanide exposure from oral nitazoxanide through pharmacokinetic interaction in healthy volunteers;2023-09-22

5. Perioperative Treatment Strategies in EGFR-Mutant Early-Stage NSCLC: Current Evidence and Future Challenges;Journal of Thoracic Oncology;2023-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3